Voclosporin

Drug Profile

Voclosporin

Alternative Names: trans-ISA 247; trans-R 1524; ISA(TX)247; ISA-247; ISAtx 247; ISATx247; Orelvo; R-1524; Voclera

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Isotechnika
  • Developer Atrium Medical Corporation; Aurinia Pharmaceuticals; Isotechnika; Paladin Labs
  • Class Antipsoriatics; Ciclosporins; Eye disorder therapies; Immunotherapies; Skin disorder therapies
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lupus nephritis
  • No development reported Renal transplant rejection
  • Discontinued Coronary artery restenosis; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 05 Jun 2017 Updated efficacy and adverse events data from the phase IIb AURA-LV trial in Lupus nephritis released by Aurinia Pharmaceuticals
  • 17 May 2017 Phase-III clinical trials in Lupus nephritis in USA (PO) (NCT03021499)
  • 28 Apr 2017 Phase-III clinical trials in Lupus nephritis in Spain, Bulgaria (PO) (EudraCT2016-004045-81)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top